O'Byrne K J, O'Hare N, Sweeney E, Freyne P J, Cullen M J
Department of Endocrinology, St James's Hospital, Dublin, Ireland.
Nucl Med Commun. 1996 Sep;17(9):810-6. doi: 10.1097/00006231-199609000-00013.
Medullary thyroid carcinoma (MTC) is a neuroendocrine tumour characterized by the production and secretion of calcitonin. MTC tumours may express functional somatostatin receptors (hSSTR). A significant proportion of hSSTR receptor-positive MTC tumours, including metastatic disease, may be visualized in vivo through 111In-pentetreotide scintigraphy. Four patients with recurrent/metastatic disease, who had previously been assessed with 111In-anti-CEA monoclonal antibody fragment [F(ab')2] imaging, were evaluated. 111In-pentetreotide scintigraphy localized all known disease sites. Furthermore, mediastinal disease was detected in one patient with negative conventional, and 111In-anti-CEA F(ab')2 imaging studies. The detection of somatostatin within the tumour (2 patients), or negative octreotide challenges (2 patients), did not affect the outcome of 111In-pentetreotide scintigraphy. In conclusion, 111In-pentetreotide scintigraphy appears at least as effective as 111In-anti-CEA F(ab')2 imaging and should be considered in the diagnostic evaluation of MTC, particularly in the setting of recurrent/metastatic disease not detected by conventional means.
甲状腺髓样癌（MTC）是一种神经内分泌肿瘤，其特征是产生和分泌降钙素。MTC肿瘤可能表达功能性生长抑素受体（hSSTR）。相当一部分hSSTR受体阳性的MTC肿瘤，包括转移性疾病，可通过111铟-喷替肽闪烁扫描在体内显影。对4例复发性/转移性疾病患者进行了评估，这些患者之前已接受过111铟-抗癌胚抗原单克隆抗体片段[F(ab')2]成像检查。111铟-喷替肽闪烁扫描定位了所有已知的疾病部位。此外，在1例传统检查及111铟-抗癌胚抗原F(ab')2成像检查均为阴性的患者中检测到了纵隔疾病。肿瘤内生长抑素的检测（2例患者）或奥曲肽激发试验阴性（2例患者）并不影响111铟-喷替肽闪烁扫描的结果。总之，111铟-喷替肽闪烁扫描似乎至少与111铟-抗癌胚抗原F(ab')2成像一样有效，在MTC的诊断评估中应予以考虑，尤其是在常规方法未检测到复发性/转移性疾病的情况下。
